Strategic Solutions for Overcoming Challenges in AI Adoption

Artificial intelligence (AI) has become a disruptive technology within modern pharmaceutical research and fundamentally overhauls the pharmaceutical discovery, development, and regulatory science paradigms. This chapter presents a comprehensive study of the scientific, operational, legal, and ethical implications of the implementation of AI in the entire drug-level process. During the early discovery stage, AI approaches, such as deep learning, generative modeling, graph neural networks, and virtual screening are improving target discovery, enhancing transition of hits to leads, and facilitating rational design of molecules on a scale never seen before. These methods improve prediction accuracy of physicochemical and ADMET properties, minimize reliance on laboratory tests (which are subsequently costly and labor intensive), and lower overall failure rates that typify preclinical pipelines in the past. With advancing maturity into clinical setting, AI assists in optimization of protocols, stratification of patients, adaptive trial designs, and detection of safety signals by real-time analytics based on electronic health records, image modalities, and biomarker data. Besides, AI-based manufacturing systems are enabling the predictive maintenance, real-time quality control, and constant optimization of the processes in terms of Quality-by-Design (QbD) and Good Manufacturing Practice (GMP) models. Tools based on AI, especially machine-learning-based models and adaptive algorithm models, raise auditing and compliance issues, particularly in respect to traceability, prejudice, accountability, and conformity to worldwide data protection frameworks, including the GDPR. This chapter also examines the approach embraced by major regulatory authorities, such as the European Union (EU), the U.S. Food and Drug Administration (FDA), and the United Kingdom (UK) and outlines various divergent philosophies, the emerging direction towards risk-based assessment, lifecycle analysis, and Good Machine Learning Practice (GMLP). To implement responsible, trustworthy deployment of AI, it is required that they are heavily validated, have strong data governance infrastructure, are transparent, audited in fairness, and subject to adaptive regulation like sandboxes. Together, these elements are the basis to leverage the maximum potential of AI and preserve the rights of the patients, the scientific integrity, and social confidence in the changing situation in the sphere of drug development.